All Sickle-cell disease articles
-
Industry newsCRISPR tool used to treat sickle-cell and β-thalassemia
Casgevy is the first gene therapy that uses the CRISPR/Cas9 gene-editing tool to be approved by the UK MHRA.
The Organisation for Professionals in Regulatory Affairs
- Contact us
- Copyright © 2015-2024 The Organisation for Professionals in Regulatory Affairs Ltd. t/a Regulatory Rapporteur - All rights reserved